Cannabix Technologies Inc. $BLOZF is Close to Commercializing a Marijuana Breath Test That Police and Industry Across the U.S. ,Canada and Europe Desperately Need

Summary

After ten years of intensive R&D study, $BLOZF has developed and is close to commercializing a Marijuana Breath Test solution.  As marijuana use has now been legalized in 38 U.S. states, police departments across the country are keen to keep THC-impaired drivers off the roads, and a key impediment to achieving this goal is the current lack of availability of a reliable, non-invasive THC breath test.  Importantly, $BLOZF’s Marijuana Breath Test (MBT) technology promises to fill that need.  The annual market for such a device is estimated to measure in the billions of U.S. dollars.  (Note that the science behind THC breath testing is much more complex than for alcohol.)  Given the large size of the market opportunity and $BLOZF’s modest valuation -- stock market capitalization of just C$63 million -- $BLOZF is an attractively priced, speculative play on a highly disruptive technology.

As cannabis use grows, the need for reliable THC detection increases as well.  (THC, also known as marijuana, is the psychoactive compound found primarily in the cannabis plant.)  More specifically, cannabis consumption is now deemed legal in 38 U.S. states, 24 of which permit it for recreational use and 14 for medical use only.  Not surprisingly, as more states have legalized cannabis, its consumption is increasing.  Indeed, a 2023 study published in the American Journal of Preventive Medicine found that frequent cannabis use has jumped to 26% from 21% among young adults aged 21-23 in states that legalized marijuana consumption.

In turn, and not surprisingly, more drivers whose judgments and driving skills are impaired by THC use are on the roads and are involved in accidents.    Indeed, the percentage of road traffic accidents in which at least one driver ultimately tested positive for THC is as high as 32%, according to one study.  However, an intractable problem is that a portable, non-invasive THC breath collection device has not -- at least yet -- been commercialized and made available to police departments.

Many obstacles must be surmounted before such a solution which produces reliable results can be utilized.  First, the chemical nature of THC makes breath testing for THC more difficult than for alcohol.  THC is fat soluble, which means the substance can be stored in fat or fatty tissues, making it detectable in the body days, weeks, or even months after the intoxicating effects have worn off.  Alcohol, on the other hand, metabolizes over predictable timeframes and easily turns into gas, allowing for relatively precise breath testing. 

Second, a THC testing solution ideally is based on breath, not urine, oral fluids, or hair fibers.  Only a breath test can best determine objectively whether the substance has been consumed within the last one to three hours, the peak window of impairment.  These other legacy methods can just show whether THC has been used in recent days, weeks, or even months, hardly conclusive indicators of current impairment. 

Finally, a breath testing device must be able to collect exhaled breath effectively where THC concentrations are extraordinarily low (measured in the trillionth of a gram).  In addition, THC in exhaled breath does not easily evaporate into a gas, making the creation of a trusted THC breath testing apparatus even a tougher task.

Cannabix Technologies Inc. $BLOZF has overcome many of these barriers.

Cannabix Technologies Inc has been researching and developing breath capture technology for ten years.  After completing Mass Spec testing (a method used in clinical diagnostics to identify and measure molecules in samples) and extensive testing of actual human breath samples, the company has developed a truly disruptive, reliable, handheld THC testing solution -- the Cannabix Marijuana Breath Test (MBT), which includes the point of care Breath Collection Unit (BCU) and the Breath Cartridge technology.

Five Reasons Cannabix Technologies Inc. $BLOZF Should Be on Your Watchlist

• Phrased simply, Cannabix has developed a unique technology product for which there is tremendous demand, in particular for portable breathalyzers.  The breathalyzer market totaled US$3.15 billion in 2024 and is expected to more than triple to US$10.9 billion by 2032.  Given the size of this opportunity and its first mover advantage, Cannabix’s share price (total stock market capitalization of just C$63 million) has enormous upside potential.
  

• Cannabix has entered into a strategic partnership with Omega Laboratories to commercialize its MBT solution.  Omega, which is a leading provider of international lab testing solutions and has 6,000 worldwide clients, announced a validation method in March 2025 which quantifies THC, cannabidiol (CBD), and cannabinol (CBN) in breath aerosols collected by Cannabix’s BCU.  Given Omega’s strong reputation in the testing community, the following statement on its website is testament to the efficacy of Cannabix’s MBT: “Omega Laboratories is confident in the reliability and accuracy of the THC breath test system.”

• Based on Omega’s analysis capability, Cannabix expects it will receive reliable test results just 24-48 hours after a breath sample is collected.

• Cannabix is also developing a companion alcohol breath testing system, the BreathLogix Alcohol Breathalyzer (Br-LGX).  The Br-LGX system is an autonomous system and is ideally suited for employers which require point of access, reliable alcohol testing.
• Cannabix’s management team combines extensive capital markets experience with advanced scientific expertise in breath analysis technology, toxicology, mass spectrometry, and portable electronic device development. The Company has also partnered with Omega Laboratories, an ANAB and CLIA-accredited facility based in Ohio, USA.